Eye Research Center (M.M., A.N., K.F.), Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran; and Noor Ophthalmology Research Center (H.H.), Noor Eye Hospital, Tehran, Iran.
Eye Contact Lens. 2020 Jan;46(1):57-62. doi: 10.1097/ICL.0000000000000604.
To evaluate the outcomes and complications of Descemet-stripping automated endothelial keratoplasty (DSAEK) in children with congenital hereditary endothelial dystrophy (CHED).
Eighteen eyes from 10 children with CHED who underwent standard phakic DSAEK were enrolled in this retrospective interventional case series. Medical records including slit-lamp biomicroscopy, cycloplegic refraction, visual acuity, and measurements of central corneal thickness, corneal topography, and endothelial cell density were evaluated. All complications were recorded.
The mean age of cases was 8.1±4.2 (range: 3-16) years at the time of surgery. Descemet-stripping automated endothelial keratoplasty was performed successfully in all eyes, which survived in 16/18 (88.9%) of cases during a median follow-up period of 38 (range 19-64) months. In patients with clear graft, best-corrected visual acuity was improved to a range of 20/100 to 20/40 and improved to fix and follow in one younger child. Endothelial cell density decreased by an average of 42.1%, comparing baseline and 6-month follow-up and was relatively stable thereafter. A marked flattening of the anterior corneal curvature (mean change of anterior K reading: +2.56±3.14 diopters) was observed after DSAEK. The only major complication in patients with clear graft was intraocular pressure elevation in 61.1% of the eyes, which was easily controlled with one antiglaucoma medication. None of the eyes developed cataract.
Descemet-stripping automated endothelial keratoplasty is a safe and successful procedure in children with an acceptable graft survival in a mid-term follow-up period. A marked hyperopic shift could occur after DSAEK in children with CHED.
评估先天性遗传性内皮营养不良(CHED)患儿行撕囊自动化角膜内皮移植术(DSAEK)的疗效和并发症。
回顾性分析 10 例(18 只眼)CHED 患儿行标准有晶状体眼 DSAEK 的临床资料。记录术中及术后视力、眼压、角膜中央厚度、角膜地形图、内皮细胞密度等,观察术后并发症。
手术时患者平均年龄为 8.1±4.2(3-16 岁)。18 只眼均成功完成 DSAEK,术后 16 只眼(88.9%)获得长期存活。随访 38(19-64)个月后,视力提高至 20/100-20/40 者 13 只眼,1 只年幼患者视力提高至能固视。术后内皮细胞密度平均下降 42.1%,术后 6 个月后基本稳定。术后所有患者前房角变浅,平均前房角曲率值增加(+2.56±3.14 屈光度)。术后眼压升高 6 只眼(61.1%),经降眼压药物治疗后眼压均控制在正常范围。无白内障发生。
DSAEK 治疗 CHED 患儿安全有效,中期随访有较高的植片存活率,术后可出现显著远视漂移。